



**KERALA MEDICAL SERVICES CORPORATION LTD.,**  
(Dept. of Health & Family Welfare, Govt. of Kerala)  
Thycaud P.O., Thiruvananthapuram-14  
Tele Fax No: 0471-2945647,  
0471-2945600  
Email id: [edrugs.kmscl@kerala.gov.in](mailto:edrugs.kmscl@kerala.gov.in)  
CIN : U24233KL2007SGC021616

Oncology Division  
No. KMSCL/ED/28-RT/2024

[www.kmscl.kerala.gov.in](http://www.kmscl.kerala.gov.in)  
Date :31.08.2024

### NOTICE

**Sub :- KMSCL – Re-tender for the Procurement of Anti-Cancer Drugs for the year 2024-25 – Technical Bid Evaluation – Defects noticed/status– Published – reg.**

**Ref :- 1. E-tender No KMSCL/ED/ACD/RT/2024/015; Dated 09.07.2024.**

Technical bids submitted in response to the e-tender referred above for the Procurement of Anti-Cancer Drugs for the year 2024-25 were opened on 31.07.2024 and scrutinized. The status is published below.

All the bidders are directed to verify the details of their offered items in the notice published.

Complaints/ suggestions/ representations, if any, on this notice shall be submitted to the Tender Inviting Authority in writing on or before **5pm on 07.09.2024**

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
Bid No. 1		M/s MSN Laboratories Pvt Ltd, Telangana			
1.	D24304C	CABOZANTINIB TAB	20 mg	1 No	1. Notary attested copy of Market Standing Certificate not submitted as per clause 5.2.5.6 for the quoted items. 2. Notary attested copy of <b>WHO</b> GMP Certificate for the manufacturing unit bearing license number <b>5/MN/TS/2014/F/G</b> for the product D24304C-CABOZANTINIB TAB 20 mg not submitted.
2.	D24242C	NILOTINIB CAP	150 mg	1 No	
3.	D24201C	NILOTINIB CAP	200 mg	1 No	

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
					<p>3. <b>Details of three batches</b> not furnished in the performance statement (<b>Annexure - IV</b>) submitted for D24304C-CABOZANTINIB TAB 20 mg</p> <p>4. Notary attested <b>copy of Performance Statement (Annexure-IV)</b> not submitted for the following;</p> <p>D24242C NILOTINIB CAP 150 mg D24201C NILOTINIB CAP 200 mg</p>
<b>Bid No. 2</b>		<b>M/s Therdose Pharma Pvt Ltd. , Telangana</b>			
1.	D24217C	TEGAFUR+URACIL CAP	100 mg +224 mg	1 No	<p>1. Notary attested copy of <b>WHO-GMP</b> certificate not submitted for the manufacturing unit bearing license number <b>02/RR/TS/2014/F/G.</b></p> <p>2. It is noted that Product Permit for the D24242C- NILOTINIB CAP 150 mg, D24201C- NILOTINIB CAP 200 mg is issued on <b>2019</b>, and the Market Standing Certificate submitted also shows that the products are having 3 year marketing. But it was noted that, NILOTINIB CAP 150mg &amp; 200 mg, was a patented molecule and the patency of the above molecules <b>has got expired on July 2023.</b> Hence 3 year Market standing certificate may not available. <b>Clarification is to be submitted.</b></p>
2.	D24242C	NILOTINIB CAP	150 mg	1 No	
3.	D24201C	NILOTINIB CAP	200 mg	1 No	

Sl. No	Drug Code	Drug Name	Strength	Unit	Defects noticed and Status
Bid no. 3		M/s Enzene Biosciences Ltd , Maharashtra			
1.	D24069C	CETUXIMAB INJ	100 mg	Vial	Submitted the required documents.

Sd/-

MANAGING DIRECTOR  
KERALA MEDICAL SERVICES CORPORATION LTD.  
(TENDER INVITING AUTHORITY)